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Opposing activities of acetyltransferases and deace-
tylases help regulate energy balance. Mice heterozy-
gous for the acetyltransferase CREB binding protein
(CBP) are lean and insulin sensitized, but how CBP
regulates energy homeostasis is unclear. In one
model, the main CBP interaction with the glucagon-
responsive factor CREB is not limiting for liver gluco-
neogenesis, whereas a second model posits that
Ser436 in the CH1 (TAZ1) domain of CBP is required
for insulin and the antidiabetic drug metformin to
inhibit CREB-mediated liver gluconeogenesis. Here
we show that conditional knockout of CBP in liver
does not decrease fasting blood glucose or gluco-
neogenic gene expression, consistent with the first
model. However, mice in which the CBP CH1 domain
structure is disrupted by deleting residues 342–
393 (DCH1) are lean and insulin sensitized, as are
p300DCH1mutants.CBPDCH1/DCH1mice remainmet-
formin responsive. An intact CH1 domain is thus
necessary for normal energy storage, but not for
the blood glucose-lowering actions of insulin and
metformin.
INTRODUCTION
Energy homeostasis, defined as the balance between energy
intake, storage, and expenditure, is regulated in part by energy-
sensing sirtuin protein deacetylases (Yu and Auwerx, 2009).
Less well understood in the control of energy balance are the
roles of protein or histone lysine acetyltransferases (HATs or
KATs), which acetylate many metabolic enzymes (Zhao et al.,
2010), as well as targets of sirtuin-mediated deacetylation
(Hirschey et al., 2010). While it is assumed that the enzymatic
activities of HATs are critical for energy balance, the roles of their
distinct domains that impart regulatory specificity by binding to
transcription factors and other proteins are less clear.
CBP (Crebbp) and the closely related p300 (Ep300) comprise
the KAT3 family of HAT transcriptional coactivators (Allis et al.,
2007).Most of the conserved regions of CBP and p300, including
those harboring acetyltransferase activity, have little sequenceCelsimilarity with other HAT families, suggesting that CBP and
p300 have unique functions (Bedford et al., 2010; Marmorstein,
2001). Indeed, CBP and p300 are required for normal develop-
ment, as loss of either one results in early embryonic lethality
in mice (Tanaka et al., 1997b; Yao et al., 1998).
Studies of nonlethal mutants have been instructive in deter-
mining the role of CBP in later development and physiology.
Mice heterozygous for a CBP null mutation are growth retarded,
as are those heterozygous for an allele that produces a truncated
form of CBP (Kung et al., 2000; Oike et al., 1999). The latter
mutant has been the more extensively characterized of the
two, and it is lean (‘‘lipodystrophic’’) and more insulin sensitive
than wild-type (WT) controls, suggesting that CBP is an impor-
tant regulator of energy homeostasis (Yamauchi et al., 2002).
In this regard, CBP is modeled as central to the counterregula-
tory effects of glucagon and insulin on gene expression that is
required for hepatic gluconeogenesis (He et al., 2009; Yamauchi
et al., 2002; Zhou et al., 2004), a critical process for maintaining
glucose homeostasis (Biddinger and Kahn, 2006).
During fasting, glucagon produced by the pancreas promotes
hepatic glucose production by increasing intracellular cyclic
AMP in the liver. Hepatic gluconeogenic gene transcription is
stimulated via the recruitment of HAT (CBP/p300) and non-HAT
(CRTC) coactivators to the cAMP-responsive transcription factor
CREB that is bound to the promoters of target genes (Herzig
et al., 2001; Koo et al., 2005). However, mice homozygous for
a mutation in CBP that ablates the interaction of CREB and the
KIX domain of CBP (Kasper et al., 2002; Xu et al., 2007) have
fasting blood glucose levels and hepatic gluconeogenic gene
expression that are similar to controls (Koo et al., 2005). This
suggests that other domains of CBP besides KIX may be critical
for glucose regulation, or that p300 (or the non-HAT CRTC2)
can compensate for KIX mutant CBP. Conversely, mice with a
serine-to-alaninemutation in theCH1domain ofCBP (Ser436Ala)
display increased hepatic gluconeogenic gene expression and
increased fasting blood glucose, and are resistant to the hypo-
glycemia-inducing effects of insulin and metformin (He et al.,
2009; Zhou et al., 2004). Since p300 lacks an equivalent serine
residue in CH1 (Figure 3A), those studies suggest that CBP has
unique insulin- and metformin-responsive properties. Thus, the
role of CBP in controlling liver gluconeogenesis is unresolved.
In this study, we inactivated CBP in the liver to further clarify
these two models for hepatic gluconeogenesis. Consistent with
earlier findings using CBP KIX domain mutant mice, we foundl Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Inc. 219
Figure 1. CBP in the Liver Is Not Limiting for Normal Fasting Blood Glucose and Gluconeogenic Gene Expression
(A) Sixteen hour fasting blood glucose in 5-month-old WT and CBPflox/flox male mice 7 days after injection with 2.5 3 1010 g.c. AAV-Cre (WT + AAV-Cre [n = 10]
and CBPflox/flox + AAV-Cre [n = 9]).
(B) IP-western of CBP and p300 using liver nuclear extracts.
(C–E) qRT-PCR analysis of mRNA for the indicated hepatic gluconeogenic genes after 16 hr fast (WT + AAV-Cre [n = 10] and CBPflox/flox + AAV-Cre [N = 9]).
(F andG) Affymetrix microarray expression signal for the indicated probe sets ofNdrg1 andPpp1r3c based onmRNA from two independent primaryMEF isolates
of each genotype (WT and CBP and p300 double null [dKO]); serum-starved MEFs were treated for 90 min with ethanol vehicle (EtOH) or cAMP agonists
forskolin + IBMX (FI), n = 2.
(H and I) Ndrg1 and Ppp1r3c expression in the livers of WT + AAV-Cre (n = 10) and CBPflox/flox + AAV-Cre (n = 9) fasted male mice. Mean ± SEM. See also
Figure S1.
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Role of the CH1 Domain in Energy Homeostasisthat hepatic CBP does not appear to be limiting for maintaining
blood glucose levels. To address whether the CH1 domain is
needed for energy homeostasis and the glucose-lowering effects
of insulin and metformin, we used mice with germline knockin
deletion mutations in CBP and p300 that severely disrupt the
structure of the domain. This revealed that the DCH1 mutation
results in lean mice that respond normally to metformin but
have an enhanced insulin response. Together, our findings
provide insight into how KAT3 acetyltransferases help maintain
energy homeostasis, and suggest that the critical site of action
for CBP in regulating glucose homeostasis is outside the liver.
RESULTS
Loss of CBP in the Liver Does Not Significantly Reduce
Fasting Blood Glucose or Hepatic Gluconeogenic Gene
Expression
Insulin- or metformin-dependent phosphorylation of CBP
Ser436 is modeled to disrupt CBP binding to CREB-driven glu-
coneogenic genes in the liver, thereby repressing their expres-
sion and glucose production (He et al., 2009). A different model
indicates that CBP is not limiting for liver gluconeogenesis220 Cell Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Incbecause a mutation in its KIX domain that inhibits binding to
CREBdoes not significantly affect that process (Koo et al., 2005).
To resolve whether CBP in the liver is necessary for glucose
homeostasis, we injected CBPflox/flox conditional knockout
mice (Kang-Decker et al., 2004) with adeno-associated virus
that expresses Cre recombinase from a liver-specific promoter
(AAV-Cre). The mice were tested 7–18 days after AAV-Cre injec-
tion, depending on the assay (see the Experimental Procedures).
We found that 16 and 6 hr fasting blood glucose levels were not
significantly different between 5-month-old male WT and
CBPflox/flox mice (p > 0.05, Figure 1A, see Figure S1A available
online), even though the mutants had markedly reduced levels
of CBP in the liver (Figure 1B, Figures S1B and S1C). A replicate
experiment using different cohorts of female (6- to 9-month-old)
and male (2- to 3-month-old) CBPflox/flox mice 7 days after AAV-
Cre injection gave similar results for 16 hr fasting blood glucose
(p > 0.05, Figures S1D and S1E). Glucose tolerance tests (GTTs,
to measure the ability of the metabolic tissues to deal with
a glucose load), and insulin tolerance tests (ITTs, to determine
the glucose lowering effect of bolus i.p. insulin injection) were
also not significantly different between WT and CBPflox/flox
male mice (p > 0.05, Figures S1F–S1I)..
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Figure 2. Insulin Injection in Fasted Wild-Type Mice Does Not Rapidly Inhibit the CREB:CBP Complex or Expression of Gluconeogenic
Genes in Liver
(A) Compared to fasted WT male mice (n = 23), refeeding for 900 (n = 4) and 1800 (n = 4) increases blood glucose, whereas insulin (0.5 IU/kg) rapidly lowers blood
glucose 300 (n = 14), 900 (n = 21), and 1800 (n = 8) after i.p. injection.
(B–D) Fasted (n = 8), insulin-treated (n = 8 for each time point), or refed (n = 4 for each time point) WT mice assayed for hepatic gluconeogenic gene expression;
one-way ANOVA with Dunnett’s post test was performed to compare each treatment to untreated fasted mice.
(E) ChIP of indicated CREB coactivators at Pck1 in the livers of fasted WT mice (n = 7 per indicated treatment); normal rabbit serum control (NRS).
(F) CBP and p300 ChIP using livers from fasted mice injected with AAV-Cre (n = 6).
(G) ChIP of CBP, p300, and CRTC2 at Pck1 in the livers of fasted and refed WT mice; significance of refed versus fasted for the indicated coactivator was
determined by ANOVA with Tukey post test (n = 7 mice per indicated treatment). Mean ± SEM. See also Figure S2.
Cell Metabolism
Role of the CH1 Domain in Energy HomeostasisWe then used qRT-PCR to measure mRNA in livers from
fasted male and female mice. Expression of the gluconeogenic
CREB target genes G6pc (glucose-6-phosphatase), Pck1
(PEPCK, phosphoenolpyruvate carboxykinase), and Ppargc1a
(PGC-1a, a master coregulator of hepatic gluconeogenic gene
transcription) were not significantly different from WT animals
(p > 0.05, male data, Figures 1C–1E, Figures S1M–S1O; female,
Figures S1J–S1L). CBP and p300 were expressed at compa-
rable levels in WT liver (Figures S1P–S1R), and in CBP null livers
we did not observe evidence for compensation by p300 or other
CREB coactivators (i.e., increased expression of p300, Crtc1,
and Crtc2 mRNAs) (p > 0.05, Figures S1S–S1U). Also arguing
against complete compensation for the loss of CBP, analysis
of the CBP/p300-dependent genes Ndrg1 and Ppp1r3c (Figures
1F and 1G; identified using CBP/p300 double-knockout [dKO]
mouse embryonic fibroblasts [MEFs] [Kasper et al., 2010]) re-
vealed they were also repressed in CBP null liver (Figures 1H
and 1I). Ndrg1 was responsive to cAMP in MEFs, suggesting it
is a CREB target (Figure 1F). Thus, there are CBP-dependent
genes in the liver, but they do not appear to be involved in
glucose homeostasis. Together these results show that CBP inCelthe liver is not limiting for gluconeogenic CREB target gene
expression or glucose homeostasis. Moreover, since CBP dele-
tion has no significant effect on these processes, it implies that
phosphorylation of CBP Ser436 in the liver is also not critical.
Insulin Does Not Rapidly Inhibit the CREB:CBP Complex
or Expression of Gluconeogenic Genes in Liver
The lack of a significant effect on glucose homeostasis when
hepatic CBP was inactivated suggests that insulin does not act
by inhibiting CBP binding at CREB target genes in the liver. To
further test this idea, we examinedwhether insulin rapidly inhibits
the CREB:CBP complex and CREB-dependent gluconeogenic
gene expression. As expected, insulin i.p. injected into WT
mice that had been fasted overnight significantly lowered blood
glucose after 30, 90, and 180 min (Figure 2A) and increased the
phosphorylation of the insulin-responsive kinase AKT in the liver
(Figure S2A). However, there was no significant effect upon
G6pc or Pck1mRNA levels 90 and 180 min after insulin injection,
whereas Ppargc1a mRNA tended to increase at 90 min, albeit
with more variability (Figures 2B–2D). A different cohort of mice
showed a similar pattern of gene expression after 30 andl Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Inc. 221
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Figure 3. CBPDCH1/DCH1 and p300DCH1/DCH1 Mice Have Normal Fasting Blood Glucose Levels but Improved Metabolic Control
(A) CH1 region deleted inCBPDCH1 and p300DCH1. Key domain elements are indicated: a helices 1–4 and 12 residues that bind three Zn2+ ions; mouse (m), human
(h), worm (Ce), fly (Dm).
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Role of the CH1 Domain in Energy Homeostasis90 min of insulin (Figures S2B–S2D). As a control for our ability
to measure the metabolic regulation of genes in the liver, we
examined mRNA levels 90 and 180 min after refeeding (which
increases both insulin and satiety hormone release) and
observed gene repression (Figures 2B–2D). Thus distinct liver
gene expression responses are seen when WT fasted mice are
either injectedwith insulin or refed, a phenomenon also observed
by Lipina et al. (Lipina et al., 2005). Tilghman et al. similarly
observed that insulin alone does not repress Pck1 protein
synthesis in fasted rats (Tilghman et al., 1974). Thus, activating
the insulin pathway in the livers of fasted mice is not sufficient
to inhibit the expression of G6pc, Pck1, and Ppargc1a. Refeed-
ing therefore appears to modulate the effect of insulin on hepatic
gluconeogenic gene expression.
To further test the model of He et al. (He et al., 2009), in which
insulin alone disrupts the CREB:CBP complex at hepatic target
genes, we performed qPCR chromatin immunoprecipitation
(ChIP) on liver tissue from insulin-treated WT mice. This showed
that the occurrence of CBP, p300, and CRTC2 (TORC2) at CREB
binding sites (CREs) in the Pck1 promoter was not attenuated by
insulin (Figure 2E). The CRTC2 ChIP signal actually increased
moderately 30 min after insulin injection. Specificity of the CBP
ChIP was confirmed using CBPflox/flox mice injected with AAV-
Cre (Figure 2F). CRTC2 and CBP ChIPs were further verified by
using antigen-peptide-blocked antibodies (Figure S2E) and
showing there was a lack of coactivator enrichment at a region
20 kb upstream of the Pck1 promoter CREB binding region
(Figure S2F). It therefore appears that insulin alone does not
rapidly inhibit the expression of Pck1 or the binding of CBP at
its promoter. Moreover, it seems unlikely that the insulin-depen-
dent phosphorylation of CBP Ser436 in the liver is critical for
repressing hepatic CREB target genes.
In contrast to i.p. insulin, refeeding for 30 or 90 min attenuated
the ChIP signals for all three coactivators (CBP, p300, and
CRTC2) at the Pck1 promoter (Figure 2G), consistent with the
reduced expression of Pck1 in response to refeeding(Figure 2C).
This suggests two things: (1) refeeding and insulin injection are
not equivalent for disrupting CREB coactivator complex forma-
tion and inhibiting transcription, and (2) the recruitment of
multiple coactivators must be inhibited to repress hepatic gluco-
neogenic gene expression, which agrees with our results using
CBP liver knockout mice.
The DCH1 Mutation in CBP and p300 Removes Critical
CH1 Domain Components
Although our data indicate that CBP in the liver is not essential for
glucose homeostasis, mice heterozygous for a CBP germline
mutation that truncates at aa 1084 (deleting 1357 residues) are(B and C) Sixteen hour fasting blood glucose in CBPDCH1/DCH1 and p300DCH1/DC
[n = 7]; female WT [n = 14], CBP+/DCH1 [n = 11], CBPDCH1/DCH1 [n = 11]; and C, ma
p300+/DCH1 [n = 9], p300DCH1/DCH1 [n = 12]).
(D–I) qRT-PCR analysis of mRNA for the indicated hepatic gluconeogenic genes a
(G–I); each dot represents a biological replicate, mean value indicated.
(J) GTT for indicated male DCH1 mutants and controls; WT (n = 31), p300+/DCH1
(K) AUC analysis of GTT data shown in (J).
(L) ITT of WT (n = 28), CBPDCH1/DCH1 (n = 9), and p300DCH1/DCH1 (n = 8) mice.
(M) AUC analysis of ITT data shown in (L).
(N) MTT for WT and CBPDCH1/DCH1 mice at 4–6 months of age; sample sizes indic
age and ITTs at 6–8 months of age. Mean ± SEM. See also Figure S3.
Cellean and insulin sensitive (Yamauchi et al., 2002). The CBP func-
tional deficiencies that lead to this phenotype are unclear,
however. One clue was provided by a report that the CH1
domain of CBP is important for transactivation in response to
insulin (Zanger et al., 2001). In addition, a S436A germline muta-
tion in CBP causes an insulin-resistant phenotype (Zhou et al.,
2004), suggesting that it is the CH1 domain that is important
for metabolic control.
We tested this idea by using mice carrying deletions in one of
the two exons that encode the CH1 (TAZ1) domain of CBP
(CBPDCH1) and p300 (p300DCH1) (Kasper et al., 2005). The dele-
tion mutations are essentially equivalent in CBP and p300 (aa
342–393 deleted for CBP, and 329–379 for p300), and remove
two of the domain’s four a helices, five Cys and His residues
that bind two of the three zinc ions in the structure, 8 of 14 resi-
dues that form the conserved hydrophobic core, andmuch of the
binding surface for HIF-1a and CITED2 (Dames et al., 2002; De
Guzman et al., 2004; Freedman et al., 2002, 2003) (Figure 3A,
Figure S3A). The hydrophobic core and binding of zinc are
essential for the structural integrity of the CH1 domain (Gu
et al., 2001; Matt et al., 2004; Newton et al., 2000), indicating
that the DCH1 mutation will inhibit the interaction with most, if
not all, CH1-binding partners. Ser436 is part of the extended
CBP CH1 a4 helix that is not removed by the DCH1 mutation
(Figure 3A, Figure S3A), although interactions between a4 and
the hydrophobic core of the domain are disrupted by the deletion
of helices a1 and a2 (De Guzman et al., 2004). Thus, whether the
hypoglycemic effects of insulin or metformin require an intact
CH1 structure can be addressed using these mice.
Improved Glucose Tolerance and Insulin Sensitivity
in CBPDCH1/DCH1 and p300DCH1/DCH1 Mice
We tested whether fasting blood glucose is affected in
CBPDCH1/DCH1 mice but found no significant effect compared
to controls (p > 0.05, Figure 3B). A similar result was obtained
using p300DCH1/DCH1 mice (p > 0.05, Figure 3C). In agreement
with the fasting glucose results, hepatic gluconeogenic gene ex-
pression was not significantly altered in fasted p300DCH1/DCH1
and CBPDCH1/DCH1 mice (2- to 3-month-old males, Figures 3D–
3F; 2- to 5-month-old females, Figures 3G–3I). Interestingly,
some, but not all, 8- to 10-month-old male CBPDCH1/DCH1 mice
showed elevated expression of G6pc, Pck1, and Ppargc1a
in the liver, although fasting blood glucose was not significantly
different from age-matched WT and p300DCH1/DCH1 mice
(Figures S3B–S3E). Comparing our results from the different
age cohorts suggests that variable gluconeogenic gene expres-
sion among older CBPDCH1/DCH1 mutants reflects an indirect
effect of their physiological status rather than a direct action ofH1 mice and controls (B, male WT [n = 18], CBP+/DCH1 [n = 14], CBPDCH1/DCH1
le WT [n = 13], p300+/DCH1 [n = 12], p300DCH1/DCH1 [n = 10]; female WT [n = 15],
fter 16 hr fast for 2- to 3-month-old males (D–F) and 2- to 5-month-old females
(n = 12), p300DCH1/DCH1 (n = 10), CBP+/DCH1 (n = 19), CBPDCH1/DCH1 (n = 9).
ated. Fasting blood glucose and GTT analyses were performed at 15 weeks of
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Figure 4. CBPDCH1/DCH1 and p300DCH1/DCH1
Mice Have Reduced WAT and Body Mass
(A) Male WAT as a percentage of total body weight
for genotypes and ages indicated (n = 5–21).
(B) Male gonadal WAT pads at 12 months of age
(right and left pads shown).
(C) Body weight profiles for male CBP DCH1 mice
(at least seven mice per genotype).
(D) BMI for maleCBPDCH1/DCH1 and p300DCH1/DCH1
mice at indicated ages (n = 5–19).
(E) Body weight profiles for male p300DCH1 mice
(at least ten mice per genotype).
(F) Average daily food intake normalized to total
body weight for WT (n = 18), p300DCH1/DCH1 (n = 7),
andCBPDCH1/DCH1 (n = 9) male mice at 4–8months
of age.
(G) H&E stain of gonadal WAT pads.
(H) Quantification of average number of cells
per field of view in WAT pad sections WT (n = 3),
CBP+/DCH1 (n = 4), CBPDCH1/DCH1 (n = 3). Mean ±
SEM. See also Figure S4.
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Role of the CH1 Domain in Energy Homeostasisthe CBPDCH1 protein on liver target genes. Nonetheless, severe
disruption of the CBP or p300 CH1 domain structure in every
tissue of the mouse does not affect fasting blood glucose, ex-
panding upon the result obtained with conditional knockout of
CBP in liver.
We next performed GTTs, as CBP S436A mutant mice are
glucose intolerant and insulin resistant (Zhou et al., 2004), while
mice heterozygous for a truncated allele of CBP (retaining CH1
but lacking the HAT domain) have increased glucose tolerance
and insulin responsiveness (Yamauchi et al., 2002). In contrast
to CBP S436A mutants, CBPDCH1/DCH1 and p300DCH1/DCH1
mice showed improved glucose tolerance relative to WT animals
(p < 0.05, Figures 3J and 3K). Improved glucose tolerance in the
DCH1 mutants indicates insulin sensitization, so we performed
ITTs. CBPDCH1/DCH1 (p < 0.05) and p300DCH1/DCH1 (p < 0.001)
mice both showed an enhanced ability to lower blood glucose
in response to insulin, indicating that their improved glucose
responsiveness was due to increased insulin sensitivity (Figures224 Cell Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Inc.3L and 3M). As CBP liver knockout mice
had normal ITT and GTT responses (Fig-
ure S1F–S1I), these results indicate that
the CH1 domain of CBP and p300 is crit-
ical outside the liver for glucose homeo-
stasis. Speculating, it might be that the
CBP truncation (Yamauchi et al., 2002)
and DCH1 mutations similarly affect
these physiological functions via related
mechanisms (e.g., inhibiting the activity
of a CH1-binding transcription factor).
CBPDCH1/DCH1 Mice Lower Their
Blood Glucose Normally
in Response to the Antidiabetic
Drug Metformin
The CBP CH1 structural domain could be
inferred to mediate the glucose-lowering
effect of metformin that occurs in re-
sponse to Ser436 phosphorylation (Heet al., 2009). To examine this, we performedmetformin tolerance
tests (MTTs). This showed that i.p. metformin lowered fasting
blood glucose levels similarly in WT and CBPDCH1/DCH1 mice
(p > 0.05) when compared to i.p. saline (Figure 3N). Thus,
disrupting the CH1 domain structure of CBP enhances insulin
sensitivity, but it does not affect the blood glucose-lowering
action of metformin.
CBPDCH1/DCH1 and p300DCH1/DCH1 Mice Have Reduced
Body Weight and White Adipose Tissue
Increased insulin responsiveness suggests enhanced metabolic
control. In line with this, CBPDCH1/DCH1 and p300DCH1/DCH1 mice
at 4–16 months of age had significantly reduced white adipose
tissue (WAT) as a percentage of body weight, which became
more apparent with age (male data, Figures 4A and 4B; female
data, Figures S4A–S4C).
Consistent with reduced WAT, CBPDCH1/DCH1 mice weighed
less thansamesexcontrols at all ages (males, Figure4C; females,
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Figure 5. CBPDCH1/DCH1;p300+/DCH1 and WT MEFs Differentiate Comparably into Adipocytes
(A) Oil red O staining of WT and CBPDCH1/DCH1;p300+/DCH1 MEFs cultured for 4 or 12 days in adipocyte-differentiation media. Two independent primary MEF
isolates of each genotype are shown.
(B–D) mRNA levels of adipogenic gene markers PPAR-gamma (Pparg), FAS (Fasn), and glucose transporter 4 (GLUT4, Slc2a4) during the first 8 days of
differentiation. n = 2 independent MEF isolates per genotype. Mean ± SEM. See also Figure S5.
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Role of the CH1 Domain in Energy HomeostasisFigure S4D). Although growth retardation of CBPDCH1/DCH1
mice accounted for part of their reduced weight, they had
a lower body mass index (BMI) than WT mice as early as
4–6 months of age (Figure 4D), indicating that their reduced
weight was not solely due to their smaller size. CBP+/DCH1
mice showed an intermediate phenotype for body weight and
BMI, especially as they aged (Figures 4C and 4D, Figure S4D).
p300DCH1/DCH1 mice were not growth retarded, yet they also
exhibited lower body weight (Figure 4E, males; Figure S4E,
females) and reduced BMI (Figure 4D). WT, CBPDCH1/DCH1,
and p300DCH1/DCH1 mice consumed similar amounts of normal
chow (data not shown), although CBPDCH1/DCH1 mutants ate
more in comparison to their body weight (p < 0.05, Figure 4F).
This indicates the reduced BMI of the DCH1 mutants is not
due to decreased food intake. Thermogenic brown adipose
tissue (BAT) might be expected to be more abundant in lean
animals, but it was actually reduced in 10- to 12-month-old
CBPDCH1/DCH1 mice relative to WT, although this difference
was not significant when normalized to body weight (p > 0.05,
Figures S4F and S4G).CelWAT Adipocytes from CBPDCH1/DCH1 Mice Are Smaller
The reduced WAT mass in DCH1 mutant mice could be caused
by fewer or smaller fat cells. Histological analysis of gonadal
WAT from 4- to 6-month-old CBPDCH1/DCH1 mice showed
that adipocytes were smaller compared to controls (p < 0.05,
Figures 4G and 4H). To help determine if the DCH1 mutation
inhibits fat synthesis or storage, we differentiated WT and
CBPDCH1/DCH1;p300+/DCH1 MEFs into adipocytes ex vivo. These
mutant adipocytes were severely deficient for normal CH1
domains, but they did not obviously differ from WT cells, as
shown by oil red O staining for lipids and the expression of
adipogenic marker genes encoding peroxisome proliferator-
activated receptor gamma (PPAR gamma, Pparg), fatty acid
synthase (FAS, Fasn), and glucose transporter-4 (GLUT4,
Slc2a4) (Figure 5). Consistent with these in vitro findings, expres-
sion of the fatty acid storage and metabolism genes Plin2,
Fabp4, Fabp5, Plin1, Cpt1b, and Acaca in WAT isolated from
8- to 10-month-old WT, CBPDCH1/DCH1, and p300DCH1/DCH1
mice was comparable (p > 0.05, Figures S5A–S5F). In addition,
fatty acid oxidation measurements (Brivet et al., 1995; Buzzail Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Inc. 225
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Figure 6. p300DCH1/DCH1Mice on a High-Fat Diet Have Improved Serum Triglycerides, Glucose Tolerance, and Insulin Sensitivity Compared
to WT Littermates
(A) Body weights of 10- to 12-month-old WT (n = 6) and p300DCH1/DCH1 (n = 5) male mice on a HFD for 12 weeks.
(B) Food intake between HFD weeks 11 and 12.
(C) Serum triglyceride levels of male mice fed the HFD for 12 weeks.
(D) GTT data obtained for WT (n = 5) and p300DCH1/DCH1 (n = 5) after 10 weeks on the HFD.
(E) ITT data for WT (n = 6) and p300DCH1/DCH1 (n = 3) mice after 12 weeks of HFD. Mean ± SEM.
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Role of the CH1 Domain in Energy Homeostasiset al., 2005) using adipocytes isolated from WAT were not obvi-
ously different between WT and mutants when normalized to
nuclear DNA, which is indicative of cell number (Figures S5G
and S5H; Figure 4G shows that the mutant adipocytes are
smaller and thus more abundant on a tissue weight basis). These
results together suggest that reduced WAT mass in DCH1
mutant mice is caused by altered energy demand or storage,
rather than abnormal adipogenesis or adipocyte fatty acid
metabolism.
p300DCH1/DCH1 Mice Are Resistant to the Adverse
Metabolic Consequences of a High-Fat Diet
The enhanced metabolic control observed in DCH1mutant mice
fed a normal chow diet suggested that they would bemore resis-
tant to the deleterious effects of a high-fat diet (HFD). We tested
this idea using 10- to 12-month-old p300DCH1/DCH1malemice. At
this age, the mutants started out relatively lean, yet after
12 weeks of HFD they still weighed significantly less than HFD
WT animals, despite similar food intake (Figures 6A and 6B).
Moreover, p300DCH1/DCH1 mice showed resistance to HFD-
induced elevated serum triglycerides, glucose intolerance, and
insulin resistance when compared to WT controls (p < 0.05,
Figures 6C–6E). Together, these findings suggest that reducing226 Cell Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier IncCH1 functionality increases metabolic control with both normal
diets and HFDs.
DISCUSSION
Using a tissue-specific conditional knockout of CBP, we
demonstrated that this HAT is not limiting in the liver for glucose
homeostasis or hepatic gluconeogenic gene expression.
However, germline mutations in CBP and p300 that severely
disrupt the structure of CH1 showed that this domain is critical
for maintaining fat reserves, although it is not limiting for the
blood glucose-lowering activities of insulin and metformin.
Consistent with their lean phenotype, both CBPDCH1/DCH1 and
p300DCH1/DCH1 mice were insulin sensitized, showing that dis-
rupting the CH1 domain improves metabolic control in vivo.
And for CBP at least, the critical organ system(s) for regulating
glucose homeostasis appears to be outside the liver. Thus,
identifying the transcription factor-binding CH1 domain as a
key component of a metabolic regulatory pathway provides
mechanistic insight into how CBP and p300 modulate energy
homeostasis.
The CH1 domain is one of the few regions of a mammalian
HAT to have been analyzed in vivo using more than one knockin.
Cell Metabolism
Role of the CH1 Domain in Energy Homeostasismutation (i.e., DCH1 and S436A mice). Our findings therefore
help reveal how this domain controls energy homeostasis, a topic
relevant to the expanding roles ascribed to acetyltransferases in
metabolism (Feige and Auwerx, 2007; Zhao et al., 2010), and the
fact that CBP and p300 act as regulatory network ‘‘hubs’’ (they
havemore than 400 described protein interaction partners) (Bed-
ford et al., 2010). With regard to CH1-binding partners, hypoxia-
inducible factor 1a (HIF-1a), which requires the CH1 domain for
its full transactivation activity (Kasper et al., 2005; Kasper and
Brindle, 2006), affects adipose tissue in complex ways (Halberg
et al., 2009; Zhang et al., 2010), but the expression of HIF target
genes Edn1,Higd1a, Slc2a1 (GLUT1), and Vegfa (VEGF) was not
repressed in WAT directly isolated from CBPDCH1/DCH1 and
p300DCH1/DCH1 mice (data not shown). Additionally, identifying
the CH1 domain as a mediator of the metabolic functions of
CBP helps clarify prior findings that implicated CBP in both
insulin-sensitized (Yamauchi et al., 2002) and insulin-resistant
phenotypes (He et al., 2009). The similar metabolic phenotype
we observe with both CBPDCH1/DCH1 and p300DCH1/DCH1 mice
argues that the role for the CH1 domain in energy homeostasis
is not specific to only one member of the KAT3 family.
The DCH1 mutation does not remove Ser436 in CBP, but the
differences between the CBPDCH1 and S436A phenotypes are
not inconsistent if the DCH1 mutation acts independently of
Ser436 phosphorylation. A role for the CH1 domain in metabolic
control that is independent of Ser436 is supported by the similar-
ities of the metabolic phenotypes of CBPDCH1/DCH1 and
p300DCH1/DCH1 mice even though p300 CH1 has a glycine at
the position comparable to Ser436. If, for example, Ser436
phosphorylation in response to insulin inhibits CBP CH1 domain
function, then the DCH1 mutation might have mimicked the
effect of this phosphorylation and promoted fasting hypogly-
cemia. We did not see this, however, as CBPDCH1/DCH1 mice
had normal fasting blood glucose levels, although they did
have an enhanced response to injected glucose or insulin.
On the other hand, if the DCH1 mutation prevents Ser436 phos-
phorylation or disrupts the ability of phospho-Ser436 to activate
CH1 (or other CBP domains or binding partners), then one might
expect CBPDCH1/DCH1 mice to be insulin resistant like S436A
mutants, which they are not. Alternatively, the CH1 domain and
Ser436 may act by independent physiological pathways. In
support of the latter model, the glucose-lowering activity of
metformin was not affected by the CBP DCH1 mutation, which
also suggests that this drug works differently from insulin. It is
important to reemphasize, however, that loss of CBP in the liver
had no measurable effect on glucose homeostasis, indicating
that the phosphorylation of hepatic CBP Ser436 is not physiolog-
ically relevant for that function.
Indeed, several of our findings are inconsistent with the model
in which CBP Ser436 phosphorylation by insulin-stimulated
PKCi/l inhibits CREB:CBP complex formation at gluconeogenic
genes in the liver, thereby reducing gluconeogenesis and blood
glucose levels (He et al., 2009; Zhou et al., 2004).
First, in contrast to a fast/refeed paradigm, we did not observe
an obvious and sustained decrease in gluconeogenic gene
mRNA levels in the livers of fasted WT mice injected with insulin.
Nor did we observe an insulin-dependent loss of CBP recruit-
ment to such genes. It is possible that our failure to observe
these phenomena was due to experimental conditions (e.g.,Celmouse strain) or approach (e.g., euglycemia was not main-
tained). Nevertheless, a reduction in gluconeogenic gene
expression would seem unlikely to contribute substantially to
an acute reduction in blood glucose in response to insulin. In
this regard, Ramnanan et al. have shown that reduced hepatic
glucose output in response to acute hyperinsulinemia in eugly-
cemic fasted canines is mostly due to changes in glycolysis
and glycogen synthesis rather than the repression of gluconeo-
genesis via downregulation of Pck1 expression (Ramnanan
et al., 2010).
Second, we showed that conditional knockout of CBP in the
liver did not significantly affect fasting blood glucose levels or
gluconeogenic gene expression. It is possible that using different
methods to reduce liver CBP (e.g., RNAi versus knockout) might
lead to different phenotypes, but the knockout data are consis-
tent with a model in which CBP in the liver is not limiting for
glucose homeostasis.
Third, we found that PKC iota (PKCi, PKCi/l, PKCl), which is
modeled as the insulin-responsive CBP Ser436 kinase in liver
(He et al., 2009), does not measurably phosphorylate Ser436
in vitro. Using purified recombinant PKCi (Promega), we did
not observe evidence for significant inducible Ser436 phosphor-
ylation with the following substrates: (1) WT, DCH1, S436A, and
DCH1/S436A CBP-HA proteins expressed in 293T cells and
immunoprecipitated with anti-HA antibody (Figures 7A and 7B);
(2) a synthetic CBP 430–442 peptide (LPLKNASDKRNQQ)
(Figure 7C); (3) endogenous CBP immunoprecipitated from
extracts prepared from serum-starved and insulin-treated
HepG2 cells (Figure S6A); (4) endogenous CBP immunoprecip-
itated from liver nuclear extracts prepared from fasted WT
mice (Figure S6B); (5) dual-affinity purified full-length GST-
CBP-310-452-FLAG proteins (WT, DCH1, S436A, and DCH1/
S436A mutants) produced in E. coli (Figures S6C and S6D).
Importantly, in each assay, PKCi was able to efficiently phos-
phorylate itself and other substrates (e.g., FLAG-CREB, GST-
CREM, CREBtide), but not CBP Ser436. The inability of PKCi
to phosphorylate CBP S436 in vitro might be explained by the
findings of Fujii et al., who showed that Asp at the +1 position
relative to Ser strongly disfavors phosphorylation by PKC,
consistent with the basophilic nature of this kinase family (Fujii
et al., 2004). Together, these results indicate that if CBP
Ser436 is phosphorylated in response to insulin, it is probably
not by PKCi. Moreover, Matsumoto et al. showed that the
conditional knockout of PKC iota (also called PKC lambda) in
the liver increases insulin sensitivity, and not Pck1 and G6pc
expression, further suggesting this kinase does not repress
gluconeogenic genes in the liver by phosphorylating CBP
Ser436 (Matsumoto et al., 2003).
The normal fasting blood glucose levels seen inCBPDCH1/DCH1
mice agreed well with the unchanged hepatic gluconeogenic
gene expression and fasting blood glucose we observed in
mice deficient in liver CBP, as well as previously published
data on CBPKIX/KIX mice (Koo et al., 2005). This suggests other
coactivators in the liver besides CBP provide redundant coacti-
vation function for hepatic gluconeogenesis even though CBP is
limiting for the expression of other genes in that organ (e.g.,
Ndrg1,Pppr1c3). This is consistent with the notion that individual
CREB target genes dictate and utilize different coactivator
mechanisms for their expression in response to cAMP (Kasperl Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Inc. 227
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A Figure 7. Purified Recombinant PKC Iota Does Not
Efficiently Phosphorylate CBP Ser436 In Vitro
(A) SDS-PAGE autoradiogram following an in vitro kinase
assay using 5 mM [33P]-ATP, 0.1 mg PKC iota (indicated),
and 293T whole-cell extract immunoprecipitates per-
formed with anti-HA or anti-FLAG monoclonal antibodies.
293T cells were transiently transfected with the indicated
expression vectors for CBP with an HA C-terminal epitope
tag, empty vector, or CREB with a FLAG tag (positive
control PKC substrate). The lower two bands of CBP-HA
appear to lack the N-terminal region that includes the CH1
domain. Autophosphorylated PKC iota indicated.
(B) Western blot with anti-HA antibody shows 5% of input
293T extract used for IP kinase assay.
(C) In vitro kinase assays using synthetic peptides
CREBtide, CBP 430–442, or water (no peptide). Data
(c.p.m.) are from two independent experiments (n = 2–3),
mean ± SEM). See also Figure S6.
Cell Metabolism
Role of the CH1 Domain in Energy Homeostasiset al., 2010; Xu et al., 2007). p300 is a prime HAT candidate to
compensate for the loss of liver CBP, and analysis of CBP and
p300 mRNA and protein levels in the liver suggests that the
two coactivators are present in comparable amounts (Figures
S1P–S1R) (Thorrez et al., 2008). The non-HAT CRTC2 may also
provide functional redundancy, as it is limiting for the expression
of certain CREB target genes in MEFs (Kasper et al., 2010), and
for Ppargc1a, Pck1, and G6pc in the liver (Le Lay et al., 2009;
Wang et al., 2010).
The metabolic functions of the CH1 domain are limiting, as
mice heterozygous for the DCH1 mutation in CBP and p300
tended to have intermediate phenotypes for adiposity and insulin
sensitivity. Moreover, p300DCH1/DCH1 mice resisted the weight
gain, glucose intolerance, and insulin resistance associated
with a HFD. These characteristics of the CH1 domain suggest
that it would be a sensitive drug target for increasing metabolic
control.228 Cell Metabolism 14, 219–230, August 3, 2011 ª2011 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animals
CBPDCH1, p300DCH1, and CBPfloxmice were previously de-
scribed (Kang-Decker et al., 2004; Kasper et al., 2005). All
studies used C57BL/6 X 129Sv F1 hybrid mice derived
fromcongenicparents.F1p300DCH1/DCH1micewerenormal
in appearance and had body lengths similar to WT animals,
whereas adult CBPDCH1/DCH1 mice were smaller and had
moderate craniofacial anomalies (Kasper et al., 2005)
(chiefly, blunt snouts, our unpublished data). All mice were
used and cared for following protocols approved by the
Institutional Animal Care and Use Committee of St. Jude.
Histology
Gonadal WAT pads were fixed with formaldehyde and
stained with hematoxylin and eosin (H&E). ImageJ soft-
ware was used to determine the number of cells for each
of four random microscope fields of view for each of four
serial sections cutR40 mM apart.
Cell Culture
CBPDCH1/DCH1;p300+/DCH1 primary MEFs were described
previously (Kasper et al., 2005). Differentiation of
CBPDCH1/DCH1;p300+/DCH1 and WT MEFs into adipocytes
was carried out as described (Tanaka et al., 1997a), using
Dulbecco’s modified Eagle’s medium (DMEM) supple-mented with 10% heat-inactivated FBS, 0.5 mM IBMX, 1 mM dexamethasone,
and 5 mg/ml insulin. This medium was renewed every other day for 12 days.
Metabolic Studies
Fasting blood glucose was measured by tail vein bleed and a Glucometer Elite
(Bayer). GTT assays were performed on mice after a 16 hr overnight fast.
Animals were injected i.p. with 20% D-glucose (2 mg/g body weight), and
blood glucose was measured at the indicated times. ITT assays were carried
out on mice fasted for 3 hr, injected i.p. with human insulin (0.75 IU /kg), and
blood glucose measured at the indicated times. MTT assays were performed
on mice fasted for 16 hr and injected i.p. with metformin (250 mg/kg) or saline
vehicle. Human recombinant insulin (Humulin N, Lilly) was used as indicated
for the animal experiments shown. Hepatic gene expression assays using
WT mice injected with 0.75 IU/kg bovine insulin purchased from Sigma
(I5500) yielded comparable results to Humulin N (data not shown).
High-Fat Diet Assays
Ten- to twelve-month-old male WT and p300DCH1/DCH1 mice were fed a HFD
ad libitum for 12 weeks (60% kcal from fat; Research Diets, NJ). Body weight
Cell Metabolism
Role of the CH1 Domain in Energy Homeostasisand food intake were monitored. GTT and ITT assays were performed (as
described above) following 10 and 12 weeks, respectively, on the HFD. Serum
triglycerides were measured using a kit (Sigma Catalog number TR0100) and
serum from retro-orbital bleeds obtained 1 hr postprandial from anesthetized
mice that had been fasted 16 hr overnight.
Cre-Mediated Deletion of CBPflox in Liver
Mice were tail vein injected with 2.5 3 1010 genome copies of AAV-2/8-LP1-
Cre (Cre expression driven by the liver-specific promoter of lipoprotein-1).
Six days postinjection, male CBPflox/flox mice and WT controls (± AAV-Cre,
as indicated) were fasted overnight for 16 hr before performing GTTs. Mice
were then assessed for 6 hr fasting blood glucose, and then ITTs were per-
formed, allowing 72 hr recovery intervals between assays. Finally, 96 hr
following the ITT, mice were fasted overnight for assessment of 16 hr fasting
blood glucose and then sacrificed to test hepatic gluconeogenic gene expres-
sion. Similar results for 16 hr fasting blood glucose and hepatic gluconeogenic
gene expression were obtained 7 days after AAV-Cre infection for male and
female CBPflox/flox mice (Figure S1). All mice within an experiment showed
comparable inactivation ofCBPflox in the liver, as determined by semiquantita-
tive PCR of genomic DNA (Kasper et al., 2006), qRT-PCR for WT CBP mRNA
that contains exon 9 (the exon deleted by Cre-mediated recombination), and
IP-western of CBP and p300 using equal volumes of liver nuclear extracts.
IP assays were performed using pooled rabbit antisera raised against the
N and C termini of CBP and p300. Western blots were performed using mouse
monoclonal antibodies against CBP (C-1) or p300 (RW128).
Quantitative RT-PCR
Real-time reverse-transcription coupled PCR was performed as previously
described (Xu et al., 2007). Samples were normalized to b-actin mRNA, and
the expression levels for each test gene were set relative to the lowest value,
which was defined as 1.
Liver ChIP
Mice were fasted for 16 hr overnight and after determination of fasting blood
glucose were either injected i.p. with 0.5 IU/kg insulin, refed, or sacrificed as
fasted controls. Blood glucose was also measured prior to sacrifice of the
insulin-treated and refed mice. Whole-cell extracts for ChIP were prepared
as described (Tuteja et al., 2008) using freshly dissected liver tissue treated
for 10 min with 3% formaldehyde, followed by an equal volume of 2.5M
glycine. ChIP assays were performed with extracts as described; qPCR
ChIP signal was normalized to input chromatin (Kasper et al., 2005).
In Vitro Kinase Assays
In vitro phosphorylation of CBP-HA was carried out (as per the manufacturer’s
instructions) using 5 mM [33P]-ATP and 0.1 mg PKC iota (Promega #V3751),and
293T whole-cell extract immunoprecipitates that had been washed sequen-
tially with RIPA buffer (1% Nonidet P-40, 0.5% deoxycholate, 50 mM Tris
[pH 7.5], 150 mM NaCl), 10 mM Tris (pH 7.5)/0.1% Nonidet P-40/300 mM
NaCl, 10 mM Tris (pH 7.5)/0.1% Nonidet P-40/150 mM NaCl, and then
50 mM Tris (pH 7.5). Buffers contained protease inhibitors and b-glycerophos-
phate. Immunoprecipitations were performed with anti-HA or anti-FLAG
monoclonal antibodies and protein G Sepharose. 293T cells were transiently
transfected with expression vectors for mouse CBP with an HA C-terminal
epitope tag, empty vector, or CREB with a FLAG tag (positive control PKC
substrate). IP kinase reactions were incubated with shaking (600 RPM) for
30 min at 30C. For kinase assays using the synthetic peptides CREBtide
(KRREILSRRPSYR, a positive control, Promega) and CBP 430–442
(LPLKNASDKRNQQ), the reactions contained 7.5 mg peptide (200 mM),
50 mM [33P]-ATP, and 20 ng PKC iota in 25 ml and were incubated for 15 min
at 30C. Peptide reactions were terminated by drying 20 ml onto P81 phospho-
cellulose paper and then washing three times with 1% phosphoric acid.
Statistics
BMI was calculated as (weight [kg])/(body length [m])2. Data are presented
as mean ± standard error of the mean (SEM). Comparisons between groups
were made by two-tailed t test or one-way analysis of variance (ANOVA)
with Tukey or Dunnett’s posttesting. Cumulative effects over time wereCelmeasured by determining the area under the curve (AUC) using Graphpad
Prism. p > 0.05 (not significant, N.S.), *p < 0.05; **p < 0.01 and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.cmet.2011.06.010.
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